Gemini Therapeutics Announces Presentation at the Ophthalmology Innovation Summit at the 2018 Annual Meeting of the American Academy of Ophthalmology (OIS@AAO)

Cambridge, Mass., October 25, 2018 – Gemini Therapeutics, , today announced that Chief Executive Officer James McLaughlin will provide a company overview at the 2018 Ophthalmology Innovation Summit at the Annual Meeting of the American Academy of Ophthalmology (OIS@AAO).

James McLaughlin will present during the “Company Showcase” session, to be held from 9:05 – 10:05 a.m. CT on Thursday, October 25, in Chicago, Il.

Gemini Therapeutics

Gemini Therapeutics is a product enginecompany using the process of redefiningage-related macular degeneration (AMD) with precision medicineto create first-in-class therapeuticsfor unmet clinical needs in the eye and throughout the body. Our ocular therapeutic candidates are matched to molecular abnormalities found in patients with high clinical need and our broad multimodal pipeline includes monoclonal antibodies, recombinant proteins and gene therapies. Launched with funding from leading life science investors and powered by academic partnerships around the world, we are developing a series of first-in-class therapeutics for dry AMD and complement-mediated diseases.

Media Contact

Sarah Sutton
Ten Bridge Communications